Ciprofloxacin versus a tobramycin/cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety.
Sequential intravenous and oral ciprofloxacin (CF) was compared with a combination of tobramycin and cefuroxime (T/C) in the treatment of serious systemic infections. Altogether 310 patients were randomized, 160 receiving CF and 150 T/C, the 2 groups being reasonably well balanced. 29 patients without infection were excluded from the analysis. Complete clinical resolution was obtained in 75% (107/143) patients receiving CF and in 78% (107/138) receiving T/C; the difference was not statistically significant. The rate of bacterial eradication in septicaemia was 72% (95% confidence interval (95% c.i.): 58-86%) for patients treated with CF and 87% (95% c.i.: 77-96%) when T/C was given, while the eradication rates in urinary tract infection were 72% (95% c.i.: 54-90%) and 45% (95% c.i.: 23-67%) for CF and T/C, respectively. Significant differences in bacteriological response for other diagnoses were not detected. Also for lower respiratory tract infections (LTRI) the clinical and bacteriological responses were quite similar, although relatively more failures occurred in CF treated patients with LRTI caused by pneumococci. The frequencies of adverse reactions were comparable, but the reactions were less serious following CF treatment. Our results indicate that CF may be used for empirical treatment of serious infections. However, if pneumococcal etiology is likely, alternative antibiotics should be used, and if necessary, coverage against anaerobic bacteria should be added.
Kalager
T
T
Department of Medicine, Buskerud Central Hospital, Drammen, Norway.
Andersen
B M
BM
Bergan
T
T
Brubakk
O
O
Bruun
J N
JN
Døskeland
B
B
Hellum
K B
KB
Hopen
G
G
von der Lippe
E
E
Rahm
V
V
D000328:Adult; D000368:Aged; D016470:Bacteremia / Q000188:drug therapy* / Q000401:mortality; D002444:Cefuroxime / Q000009:adverse effects / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000401:mortality; D014031:Tobramycin / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000188:drug therapy* / Q000401:mortality
D002939:Ciprofloxacin; D002444:Cefuroxime; D014031:Tobramycin